These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 29986850

  • 1. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.
    Kheder ES, Hong DS.
    Clin Cancer Res; 2018 Dec 01; 24(23):5807-5814. PubMed ID: 29986850
    [Abstract] [Full Text] [Related]

  • 2. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N, McDermott R.
    Expert Rev Clin Pharmacol; 2019 Oct 01; 12(10):931-939. PubMed ID: 31469968
    [Abstract] [Full Text] [Related]

  • 3. TRK inhibition in soft tissue sarcomas: A comprehensive review.
    Assi T, Rassy E, Nassereddine H, Farhat F, Karak FE, Kattan J, Ghosn M.
    Semin Oncol; 2020 Feb 01; 47(1):73-84. PubMed ID: 32201016
    [Abstract] [Full Text] [Related]

  • 4. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 01; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [Abstract] [Full Text] [Related]

  • 5. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F, Rudzinski ER, Sepulveda AR.
    J Clin Pathol; 2019 Jul 01; 72(7):460-467. PubMed ID: 31072837
    [Abstract] [Full Text] [Related]

  • 6. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ, Zehir A, Sireci AN, Aisner DL.
    J Mol Diagn; 2019 Jul 01; 21(4):553-571. PubMed ID: 31075511
    [Abstract] [Full Text] [Related]

  • 7. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 01; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
    [Abstract] [Full Text] [Related]

  • 8. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
    Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S.
    Ann Oncol; 2019 Nov 01; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators.
    Lancet Oncol; 2020 Feb 01; 21(2):271-282. PubMed ID: 31838007
    [Abstract] [Full Text] [Related]

  • 11. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer.
    Wong D, Yip S, Sorensen PH.
    Pathol Oncol Res; 2020 Jul 01; 26(3):1385-1399. PubMed ID: 31256325
    [Abstract] [Full Text] [Related]

  • 12. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW, Hong DS.
    Clin Cancer Res; 2021 Sep 15; 27(18):4974-4982. PubMed ID: 33893159
    [Abstract] [Full Text] [Related]

  • 13. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.
    Lancet Oncol; 2018 May 15; 19(5):705-714. PubMed ID: 29606586
    [Abstract] [Full Text] [Related]

  • 14. Targeting TRK family proteins in cancer.
    Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.
    Pharmacol Ther; 2017 May 15; 173():58-66. PubMed ID: 28174090
    [Abstract] [Full Text] [Related]

  • 15. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
    Klink AJ, Kavati A, Gassama AT, Kozlek T, Gajra A, Antoine R.
    Target Oncol; 2022 May 15; 17(3):321-328. PubMed ID: 35716252
    [Abstract] [Full Text] [Related]

  • 16. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
    Kummar S, Lassen UN.
    Target Oncol; 2018 Oct 15; 13(5):545-556. PubMed ID: 30276762
    [Abstract] [Full Text] [Related]

  • 17. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
    Naito Y, Mishima S, Akagi K, Igarashi A, Ikeda M, Okano S, Kato S, Takano T, Tsuchihara K, Terashima K, Nishihara H, Nishiyama H, Hiyama E, Hirasawa A, Hosoi H, Maeda O, Yatabe Y, Okamoto W, Ono S, Kajiyama H, Nagashima F, Hatanaka Y, Miyachi M, Kodera Y, Yoshino T, Taniguchi H.
    Int J Clin Oncol; 2020 Mar 15; 25(3):403-417. PubMed ID: 31974683
    [Abstract] [Full Text] [Related]

  • 18. Phase separation underlies signaling activation of oncogenic NTRK fusions.
    Zhu T, Xie J, He H, Li H, Tang X, Wang S, Li Z, Tian Y, Li L, Zhu J, Zhu G.
    Proc Natl Acad Sci U S A; 2023 Oct 17; 120(42):e2219589120. PubMed ID: 37812694
    [Abstract] [Full Text] [Related]

  • 19. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
    Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O.
    J Clin Invest; 2018 Aug 31; 128(9):3819-3825. PubMed ID: 29920189
    [Abstract] [Full Text] [Related]

  • 20. Oncogenic fusions: Targeting NTRK.
    Hagopian G, Nagasaka M.
    Crit Rev Oncol Hematol; 2024 Feb 31; 194():104234. PubMed ID: 38122917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.